May 18, 2020 / 11:41 AM / 16 days ago

BRIEF-Moderna Announces Positive Interim Phase 1 Data For Its mRNA Vaccine Against Novel Coronavirus

May 18 (Reuters) - Moderna Inc:

* MODERNA ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR ITS MRNA VACCINE (MRNA-1273) AGAINST NOVEL CORONAVIRUS

* MODERNA INC - MRNA-1273 WAS GENERALLY SAFE AND WELL TOLERATED

* MODERNA INC - ANTICIPATED DOSE FOR PHASE 3 STUDY BETWEEN 25 ΜG AND 100 ΜG; EXPECTED TO START IN JULY

* MODERNA INC - MRNA-1273 PROVIDED FULL PROTECTION AGAINST VIRAL REPLICATION IN LUNGS IN A MOUSE CHALLENGE MODEL

* MODERNA INC - MRNA-1273 WAS GENERALLY SAFE AND WELL TOLERATED

* MODERNA INC - ANTICIPATED DOSE FOR PHASE 3 STUDY BETWEEN 25 ΜG AND 100 ΜG; EXPECTED TO START IN JULY

* MODERNA INC - MRNA-1273 ELICITED NEUTRALIZING ANTIBODY TITER LEVELS IN ALL EIGHT INITIAL PARTICIPANTS ACROSS 25 ΜG AND 100 ΜG DOSE COHORTS

* MODERNA INC - TO DATE, MOST NOTABLE ADVERSE EVENTS WERE SEEN AT 250 ΜG DOSE LEVEL

* MODERNA INC - ALL ADVERSE EVENTS HAVE BEEN TRANSIENT AND SELF-RESOLVING

* MODERNA INC - NO GRADE 4 ADVERSE EVENTS OR SERIOUS ADVERSE EVENTS HAVE BEEN REPORTED.

* MODERNA INC - MODERNA-LED PHASE 2 STUDY WILL BE AMENDED TO STUDY TWO DOSE LEVELS, 50 ΜG AND 100 ΜG

* MODERNA INC - NIAID-LED PHASE 1 STUDY IS BEING AMENDED TO INCLUDE A 50 ΜG DOSE LEVEL COHORT ACROSS EACH OF THREE AGE GROUPS. Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below